ID   TRAF6_HUMAN             Reviewed;         522 AA.
AC   Q9Y4K3; A6NKI7; A8KAB3; D3DR16; Q8NEH5;
DT   09-MAY-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1999, sequence version 1.
DT   18-JUN-2025, entry version 251.
DE   RecName: Full=TNF receptor-associated factor 6;
DE            EC=2.3.2.27 {ECO:0000269|PubMed:17135271, ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:23514740, ECO:0000269|PubMed:27746020};
DE   AltName: Full=E3 ubiquitin-protein ligase TRAF6;
DE   AltName: Full=Interleukin-1 signal transducer;
DE   AltName: Full=RING finger protein 85;
DE   AltName: Full=RING-type E3 ubiquitin transferase TRAF6 {ECO:0000305};
GN   Name=TRAF6; Synonyms=RNF85;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND INTERACTION WITH IRAK1.
RX   PubMed=8837778; DOI=10.1038/383443a0;
RA   Cao Z., Xiong J., Takeuchi M., Kurama T., Goeddel D.V.;
RT   "TRAF6 is a signal transducer for interleukin-1.";
RL   Nature 383:443-446(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   INTERACTION WITH MAP3K14.
RX   PubMed=9020361; DOI=10.1038/385540a0;
RA   Malinin N.L., Boldin M.P., Kovalenko A.V., Wallach D.;
RT   "MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-
RT   1.";
RL   Nature 385:540-544(1997).
RN   [8]
RP   INTERACTION WITH IRAK2.
RX   PubMed=9374458; DOI=10.1126/science.278.5343.1612;
RA   Muzio M., Ni J., Feng P., Dixit V.M.;
RT   "IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1
RT   signaling.";
RL   Science 278:1612-1615(1997).
RN   [9]
RP   INTERACTION WITH RIPK2.
RX   PubMed=9642260; DOI=10.1074/jbc.273.27.16968;
RA   McCarthy J.V., Ni J., Dixit V.M.;
RT   "RIP2 is a novel NF-kappaB-activating and cell death-inducing kinase.";
RL   J. Biol. Chem. 273:16968-16975(1998).
RN   [10]
RP   INTERACTION WITH TNFRSF11A.
RX   PubMed=9774460; DOI=10.1074/jbc.273.43.28355;
RA   Wong B.R., Josien R., Lee S.Y., Vologodskaia M., Steinman R.M., Choi Y.;
RT   "The TRAF family of signal transducers mediates NF-kappaB activation by the
RT   TRANCE receptor.";
RL   J. Biol. Chem. 273:28355-28359(1998).
RN   [11]
RP   INTERACTION WITH TNFRSF5.
RX   PubMed=9432981; DOI=10.1084/jem.187.2.237;
RA   Kashiwada M., Shirakata Y., Inoue J., Nakano H., Okazaki K., Okumura K.,
RA   Yamamoto T., Nagaoka H., Takemori T.;
RT   "Tumor necrosis factor receptor-associated factor 6 (TRAF6) stimulates
RT   extracellular signal-regulated kinase (ERK) activity in CD40 signaling
RT   along a ras-independent pathway.";
RL   J. Exp. Med. 187:237-244(1998).
RN   [12]
RP   INTERACTION WITH MAP3K5.
RX   PubMed=9774977; DOI=10.1016/s1097-2765(00)80283-x;
RA   Nishitoh H., Saitoh M., Mochida Y., Takeda K., Nakano H., Rothe M.,
RA   Miyazono K., Ichijo H.;
RT   "ASK1 is essential for JNK/SAPK activation by TRAF2.";
RL   Mol. Cell 2:389-395(1998).
RN   [13]
RP   INTERACTION WITH MAP3K1.
RX   PubMed=10346818; DOI=10.1101/gad.13.10.1297;
RA   Baud V., Liu Z.-G., Bennett B., Suzuki N., Xia Y., Karin M.;
RT   "Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6
RT   is sufficient for JNK and IKK activation and target gene induction via an
RT   amino-terminal effector domain.";
RL   Genes Dev. 13:1297-1308(1999).
RN   [14]
RP   INTERACTION WITH NGFR.
RX   PubMed=9915784; DOI=10.1074/jbc.274.5.2597;
RA   Khursigara G., Orlinick J.R., Chao M.V.;
RT   "Association of the p75 neurotrophin receptor with TRAF6.";
RL   J. Biol. Chem. 274:2597-2600(1999).
RN   [15]
RP   INTERACTION WITH IRAK3.
RX   PubMed=10383454; DOI=10.1074/jbc.274.27.19403;
RA   Wesche H., Gao X., Li X., Kirschning C.J., Stark G.R., Cao Z.;
RT   "IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated
RT   kinase (IRAK) family.";
RL   J. Biol. Chem. 274:19403-19410(1999).
RN   [16]
RP   INTERACTION WITH NGFR.
RX   PubMed=10514511; DOI=10.1074/jbc.274.42.30202;
RA   Ye X., Mehlen P., Rabizadeh S., VanArsdale T., Zhang H., Shin H.,
RA   Wang J.J.L., Leo E., Zapata J.M., Hauser C.A., Reed J.C., Bredesen D.E.;
RT   "TRAF family proteins interact with the common neurotrophin receptor and
RT   modulate apoptosis induction.";
RL   J. Biol. Chem. 274:30202-30208(1999).
RN   [17]
RP   INTERACTION WITH TNFRSF11A AND CSK.
RX   PubMed=10635328; DOI=10.1016/s1097-2765(00)80232-4;
RA   Wong B.R., Besser D., Kim N., Arron J.R., Vologodskaia M., Hanafusa H.,
RA   Choi Y.;
RT   "TRANCE, a TNF family member, activates Akt/PKB through a signaling complex
RT   involving TRAF6 and c-Src.";
RL   Mol. Cell 4:1041-1049(1999).
RN   [18]
RP   INTERACTION WITH MAP3K7 AND TAB1.
RX   PubMed=10094049; DOI=10.1038/18465;
RA   Ninomiya-Tsuji J., Kishimoto K., Hiyama A., Inoue J., Cao Z., Matsumoto K.;
RT   "The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase
RT   cascade in the IL-1 signalling pathway.";
RL   Nature 398:252-256(1999).
RN   [19]
RP   INTERACTION WITH MAP3K5.
RX   PubMed=10523862; DOI=10.1038/sj.onc.1202975;
RA   Hoeflich K.P., Yeh W.C., Yao Z., Mak T.W., Woodgett J.R.;
RT   "Mediation of TNF receptor-associated factor effector functions by
RT   apoptosis signal-regulating kinase-1 (ASK1).";
RL   Oncogene 18:5814-5820(1999).
RN   [20]
RP   INTERACTION WITH UBE2V1, AND FUNCTION AS AN E3 UBIQUITIN LIGASE.
RX   PubMed=11057907; DOI=10.1016/s0092-8674(00)00126-4;
RA   Deng L., Wang C., Spencer E., Yang L., Braun A., You J., Slaughter C.,
RA   Pickart C., Chen Z.J.;
RT   "Activation of the IkappaB kinase complex by TRAF6 requires a dimeric
RT   ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain.";
RL   Cell 103:351-361(2000).
RN   [21]
RP   INTERACTION WITH TDP2.
RX   PubMed=10764746; DOI=10.1074/jbc.m000531200;
RA   Pype S., Declercq W., Ibrahimi A., Michiels C., Van Rietschoten J.G.I.,
RA   Dewulf N., de Boer M., Vandenabeele P., Huylebroeck D., Remacle J.E.;
RT   "TTRAP, a novel protein that associates with CD40, tumor necrosis factor
RT   (TNF) receptor-75 and TNF receptor-associated factors (TRAFs), and that
RT   inhibits nuclear factor-kappa B activation.";
RL   J. Biol. Chem. 275:18586-18593(2000).
RN   [22]
RP   INTERACTION WITH TNFRSF17.
RX   PubMed=10908663; DOI=10.1073/pnas.160213497;
RA   Shu H.-B., Johnson H.;
RT   "B cell maturation protein is a receptor for the tumor necrosis factor
RT   family member TALL-1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:9156-9161(2000).
RN   [23]
RP   INTERACTION WITH TAX1BP1.
RX   PubMed=10920205; DOI=10.1073/pnas.170279097;
RA   Ling L., Goeddel D.V.;
RT   "T6BP, a TRAF6-interacting protein involved in IL-1 signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:9567-9572(2000).
RN   [24]
RP   UBIQUITINATION.
RX   PubMed=11460167; DOI=10.1038/35085597;
RA   Wang C., Deng L., Hong M., Akkaraju G.R., Inoue J., Chen Z.J.;
RT   "TAK1 is a ubiquitin-dependent kinase of MKK and IKK.";
RL   Nature 412:346-351(2001).
RN   [25]
RP   INTERACTION WITH TRAF3IP2.
RX   PubMed=12459498; DOI=10.1016/s0014-5793(02)03688-8;
RA   Kanamori M., Kai C., Hayashizaki Y., Suzuki H.;
RT   "NF-kappaB activator Act1 associates with IL-1/Toll pathway adapter
RT   molecule TRAF6.";
RL   FEBS Lett. 532:241-246(2002).
RN   [26]
RP   INTERACTION WITH ZNF675.
RX   PubMed=11751921; DOI=10.1074/jbc.m110964200;
RA   Shin J.N., Kim I., Lee J.S., Koh G.Y., Lee Z.H., Kim H.-H.;
RT   "A novel zinc finger protein that inhibits osteoclastogenesis and the
RT   function of tumor necrosis factor receptor-associated factor 6.";
RL   J. Biol. Chem. 277:8346-8353(2002).
RN   [27]
RP   INTERACTION WITH IRAK4.
RX   PubMed=11960013; DOI=10.1073/pnas.082100399;
RA   Li S., Strelow A., Fontana E.J., Wesche H.;
RT   "IRAK4: a novel member of the IRAK family with the properties of an IRAK-
RT   kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:5567-5572(2002).
RN   [28]
RP   INTERACTION WITH PELI1.
RX   PubMed=12496252; DOI=10.1074/jbc.m212112200;
RA   Jiang Z., Johnson H.J., Nie H., Qin J., Bird T.A., Li X.;
RT   "Pellino 1 is required for interleukin-1 (IL-1)-mediated signaling through
RT   its interaction with the IL-1 receptor-associated kinase 4 (IRAK4)-IRAK-
RT   tumor necrosis factor receptor-associated factor 6 (TRAF6) complex.";
RL   J. Biol. Chem. 278:10952-10956(2003).
RN   [29]
RP   INTERACTION WITH PELI1 AND PELI2.
RX   PubMed=12804775; DOI=10.1016/s0014-5793(03)00533-7;
RA   Jensen L.E., Whitehead A.S.;
RT   "Pellino2 activates the mitogen activated protein kinase pathway.";
RL   FEBS Lett. 545:199-202(2003).
RN   [30]
RP   INTERACTION WITH TICAM2.
RX   PubMed=12721283; DOI=10.1074/jbc.m303451200;
RA   Bin L.-H., Xu L.-G., Shu H.-B.;
RT   "TIRP, a novel Toll/interleukin-1 receptor (TIR) domain-containing adapter
RT   protein involved in TIR signaling.";
RL   J. Biol. Chem. 278:24526-24532(2003).
RN   [31]
RP   INTERACTION WITH PELI3.
RX   PubMed=12874243; DOI=10.4049/jimmunol.171.3.1500;
RA   Jensen L.E., Whitehead A.S.;
RT   "Pellino3, a novel member of the Pellino protein family, promotes
RT   activation of c-Jun and Elk-1 and may act as a scaffolding protein.";
RL   J. Immunol. 171:1500-1506(2003).
RN   [32]
RP   INTERACTION WITH TICAM1.
RX   PubMed=14530355; DOI=10.4049/jimmunol.171.8.4304;
RA   Sato S., Sugiyama M., Yamamoto M., Watanabe Y., Kawai T., Takeda K.,
RA   Akira S.;
RT   "Toll/IL-1 receptor domain-containing adapter inducing IFN-beta (TRIF)
RT   associates with TNF receptor-associated factor 6 and TANK-binding kinase 1,
RT   and activates two distinct transcription factors, NF-kappa B and IFN-
RT   regulatory factor-3, in the Toll-like receptor signaling.";
RL   J. Immunol. 171:4304-4310(2003).
RN   [33]
RP   INTERACTION WITH TICAM1.
RX   PubMed=14739303; DOI=10.1074/jbc.m311629200;
RA   Han K.J., Su X., Xu L.-G., Bin L.H., Zhang J., Shu H.-B.;
RT   "Mechanisms of the TRIF-induced interferon-stimulated response element and
RT   NF-kappaB activation and apoptosis pathways.";
RL   J. Biol. Chem. 279:15652-15661(2004).
RN   [34]
RP   INTERACTION WITH ZFAND5.
RX   PubMed=14754897; DOI=10.1074/jbc.m309491200;
RA   Huang J., Teng L., Li L., Liu T., Li L., Chen D., Xu L.-G., Zhai Z.,
RA   Shu H.-B.;
RT   "ZNF216 is an A20-like and IkappaB kinase gamma-interacting inhibitor of
RT   NFkappaB activation.";
RL   J. Biol. Chem. 279:16847-16853(2004).
RN   [35]
RP   INTERACTION WITH EIF2AK2.
RX   PubMed=15121867; DOI=10.1128/mcb.24.10.4502-4512.2004;
RA   Gil J., Garcia M.A., Gomez-Puertas P., Guerra S., Rullas J., Nakano H.,
RA   Alcami J., Esteban M.;
RT   "TRAF family proteins link PKR with NF-kappa B activation.";
RL   Mol. Cell. Biol. 24:4502-4512(2004).
RN   [36]
RP   INTERACTION WITH TICAM1.
RX   PubMed=14982987; DOI=10.1073/pnas.0308496101;
RA   Jiang Z., Mak T.W., Sen G., Li X.;
RT   "Toll-like receptor 3-mediated activation of NF-kappaB and IRF3 diverges at
RT   Toll-IL-1 receptor domain-containing adapter inducing IFN-beta.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:3533-3538(2004).
RN   [37]
RP   INTERACTION WITH MAVS.
RX   PubMed=16125763; DOI=10.1016/j.cell.2005.08.012;
RA   Seth R.B., Sun L., Ea C.-K., Chen Z.J.;
RT   "Identification and characterization of MAVS, a mitochondrial antiviral
RT   signaling protein that activates NF-kappaB and IRF 3.";
RL   Cell 122:669-682(2005).
RN   [38]
RP   INTERACTION WITH IL1RL1.
RX   PubMed=16286016; DOI=10.1016/j.immuni.2005.09.015;
RA   Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T.K.,
RA   Zurawski G., Moshrefi M., Qin J., Li X., Gorman D.M., Bazan J.F.,
RA   Kastelein R.A.;
RT   "IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-
RT   related protein ST 2 and induces T helper type 2-associated cytokines.";
RL   Immunity 23:479-490(2005).
RN   [39]
RP   INTERACTION WITH TRAFD1.
RX   PubMed=16221674; DOI=10.1074/jbc.m508221200;
RA   Mashima R., Saeki K., Aki D., Minoda Y., Takaki H., Sanada T.,
RA   Kobayashi T., Aburatani H., Yamanashi Y., Yoshimura A.;
RT   "FLN29, a novel interferon- and LPS-inducible gene acting as a negative
RT   regulator of toll-like receptor signaling.";
RL   J. Biol. Chem. 280:41289-41297(2005).
RN   [40]
RP   INTERACTION WITH MAVS.
RX   PubMed=16153868; DOI=10.1016/j.molcel.2005.08.014;
RA   Xu L.-G., Wang Y.-Y., Han K.-J., Li L.-Y., Zhai Z., Shu H.-B.;
RT   "VISA is an adapter protein required for virus-triggered IFN-beta
RT   Signaling.";
RL   Mol. Cell 19:727-740(2005).
RN   [41]
RP   INTERACTION WITH AJUBA.
RX   PubMed=15870274; DOI=10.1128/mcb.25.10.4010-4022.2005;
RA   Feng Y., Longmore G.D.;
RT   "The LIM protein Ajuba influences interleukin-1-induced NF-kappaB
RT   activation by affecting the assembly and activity of the protein kinase
RT   Czeta/p62/TRAF6 signaling complex.";
RL   Mol. Cell. Biol. 25:4010-4022(2005).
RN   [42]
RP   FUNCTION IN TRANSCRIPTIONAL ACTIVATION OF NF-KAPPA-B AND JUN, AND
RP   INTERACTION WITH ARRB1 AND ARRB2.
RX   PubMed=16378096; DOI=10.1038/ni1294;
RA   Wang Y., Tang Y., Teng L., Wu Y., Zhao X., Pei G.;
RT   "Association of beta-arrestin and TRAF6 negatively regulates Toll-like
RT   receptor-interleukin 1 receptor signaling.";
RL   Nat. Immunol. 7:139-147(2006).
RN   [43]
RP   IDENTIFICATION IN COMPLEX WITH IRAK1; IRAK4; MYD88 AND PELI1.
RX   PubMed=16951688; DOI=10.1038/ni1383;
RA   Choi K.C., Lee Y.S., Lim S., Choi H.K., Lee C.H., Lee E.K., Hong S.,
RA   Kim I.H., Kim S.J., Park S.H.;
RT   "Smad6 negatively regulates interleukin 1-receptor-Toll-like receptor
RT   signaling through direct interaction with the adapter Pellino-1.";
RL   Nat. Immunol. 7:1057-1065(2006).
RN   [44]
RP   MUTAGENESIS OF CYS-70 AND LYS-124, UBIQUITINATION AT LYS-124, FUNCTION, AND
RP   CATALYTIC ACTIVITY.
RX   PubMed=17135271; DOI=10.1074/jbc.m609503200;
RA   Lamothe B., Besse A., Campos A.D., Webster W.K., Wu H., Darnay B.G.;
RT   "Site-specific Lys-63-linked tumor necrosis factor receptor-associated
RT   factor 6 auto-ubiquitination is a critical determinant of I kappa B kinase
RT   activation.";
RL   J. Biol. Chem. 282:4102-4112(2007).
RN   [45]
RP   INTERACTION WITH RBCK1.
RX   PubMed=17449468; DOI=10.1074/jbc.m701913200;
RA   Tian Y., Zhang Y., Zhong B., Wang Y.Y., Diao F.C., Wang R.P., Zhang M.,
RA   Chen D.Y., Zhai Z.H., Shu H.B.;
RT   "RBCK1 negatively regulates tumor necrosis factor- and interleukin-1-
RT   triggered NF-kappaB activation by targeting TAB2/3 for degradation.";
RL   J. Biol. Chem. 282:16776-16782(2007).
RN   [46]
RP   FUNCTION, AND INTERACTION WITH TAX1BP1.
RX   PubMed=17703191; DOI=10.1038/sj.emboj.7601823;
RA   Shembade N., Harhaj N.S., Liebl D.J., Harhaj E.W.;
RT   "Essential role for TAX1BP1 in the termination of TNF-alpha-, IL-1- and
RT   LPS-mediated NF-kappaB and JNK signaling.";
RL   EMBO J. 26:3910-3922(2007).
RN   [47]
RP   SUBCELLULAR LOCATION, FUNCTION, SUMOYLATION AT LYS-124; LYS-142 AND
RP   LYS-453, UBIQUITINATION, INTERACTION WITH HDAC1 AND RANGAP1, AND
RP   MUTAGENESIS OF LYS-124; LYS-142 AND LYS-453.
RX   PubMed=18093978; DOI=10.1074/jbc.m706307200;
RA   Pham L.V., Zhou H.J., Lin-Lee Y.C., Tamayo A.T., Yoshimura L.C., Fu L.,
RA   Darnay B.G., Ford R.J.;
RT   "Nuclear tumor necrosis factor receptor-associated factor 6 in lymphoid
RT   cells negatively regulates c-Myb-mediated transactivation through small
RT   ubiquitin-related modifier-1 modification.";
RL   J. Biol. Chem. 283:5081-5089(2008).
RN   [48]
RP   FUNCTION IN UBIQUITINATION OR IRAK1.
RX   PubMed=18347055; DOI=10.1128/mcb.02098-07;
RA   Conze D.B., Wu C.J., Thomas J.A., Landstrom A., Ashwell J.D.;
RT   "Lys63-linked polyubiquitination of IRAK-1 is required for interleukin-1
RT   receptor- and toll-like receptor-mediated NF-kappaB activation.";
RL   Mol. Cell. Biol. 28:3538-3547(2008).
RN   [49]
RP   FUNCTION, INTERACTION WITH TGFBR1, AND UBIQUITINATION.
RX   PubMed=18758450; DOI=10.1038/ncb1780;
RA   Sorrentino A., Thakur N., Grimsby S., Marcusson A., von Bulow V.,
RA   Schuster N., Zhang S., Heldin C.H., Landstrom M.;
RT   "The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor
RT   kinase-independent manner.";
RL   Nat. Cell Biol. 10:1199-1207(2008).
RN   [50]
RP   INTERACTION WITH DYNC2I2.
RX   PubMed=19521662; DOI=10.1007/s00018-009-0059-6;
RA   Gao D., Wang R., Li B., Yang Y., Zhai Z., Chen D.Y.;
RT   "WDR34 is a novel TAK1-associated suppressor of the IL-1R/TLR3/TLR4-induced
RT   NF-kappaB activation pathway.";
RL   Cell. Mol. Life Sci. 66:2573-2584(2009).
RN   [51]
RP   FUNCTION, AND UBIQUITINATION.
RX   PubMed=19675569; DOI=10.1038/nature08247;
RA   Xia Z.-P., Sun L., Chen X., Pineda G., Jiang X., Adhikari A., Zeng W.,
RA   Chen Z.J.;
RT   "Direct activation of protein kinases by unanchored polyubiquitin chains.";
RL   Nature 461:114-119(2009).
RN   [52]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=19713527; DOI=10.1126/science.1175065;
RA   Yang W.-L., Wang J., Chan C.-H., Lee S.-W., Campos A.D., Lamothe B.,
RA   Hur L., Grabiner B.C., Lin X., Darnay B.G., Lin H.-K.;
RT   "The E3 ligase TRAF6 regulates Akt ubiquitination and activation.";
RL   Science 325:1134-1138(2009).
RN   [53]
RP   FUNCTION, UBIQUITINATION AT LYS-124, MUTAGENESIS OF CYS-70 AND LYS-124, AND
RP   INTERACTION WITH IL17RA AND TRAF3IP2.
RX   PubMed=19825828; DOI=10.1126/scisignal.2000382;
RA   Liu C., Qian W., Qian Y., Giltiay N.V., Lu Y., Swaidani S., Misra S.,
RA   Deng L., Chen Z.J., Li X.;
RT   "Act1, a U-box E3 ubiquitin ligase for IL-17 signaling.";
RL   Sci. Signal. 2:ra63-ra63(2009).
RN   [54]
RP   INTERACTION WITH NUMBL.
RX   PubMed=20079715; DOI=10.1016/j.bbrc.2010.01.037;
RA   Zhou L., Ma Q., Shi H., Huo K.;
RT   "NUMBL interacts with TRAF6 and promotes the degradation of TRAF6.";
RL   Biochem. Biophys. Res. Commun. 392:409-414(2010).
RN   [55]
RP   INTERACTION WITH TOMM70.
RX   PubMed=20628368; DOI=10.1038/cr.2010.103;
RA   Liu X.Y., Wei B., Shi H.X., Shan Y.F., Wang C.;
RT   "Tom70 mediates activation of interferon regulatory factor 3 on
RT   mitochondria.";
RL   Cell Res. 20:994-1011(2010).
RN   [56]
RP   INTERACTION WITH CARD14.
RX   PubMed=21302310; DOI=10.1002/jcp.22667;
RA   Scudiero I., Zotti T., Ferravante A., Vessichelli M., Vito P., Stilo R.;
RT   "Alternative splicing of CARMA2/CARD14 transcripts generates protein
RT   variants with differential effect on NF-kappaB activation and endoplasmic
RT   reticulum stress-induced cell death.";
RL   J. Cell. Physiol. 226:3121-3131(2011).
RN   [57]
RP   INTERACTION WITH IFIT3.
RX   PubMed=21813773; DOI=10.4049/jimmunol.1100963;
RA   Liu X.Y., Chen W., Wei B., Shan Y.F., Wang C.;
RT   "IFN-induced TPR protein IFIT3 potentiates antiviral signaling by bridging
RT   MAVS and TBK1.";
RL   J. Immunol. 187:2559-2568(2011).
RN   [58]
RP   INTERACTION WITH SASH1.
RX   PubMed=23776175; DOI=10.4049/jimmunol.1200583;
RA   Dauphinee S.M., Clayton A., Hussainkhel A., Yang C., Park Y.J.,
RA   Fuller M.E., Blonder J., Veenstra T.D., Karsan A.;
RT   "SASH1 is a scaffold molecule in endothelial TLR4 signaling.";
RL   J. Immunol. 191:892-901(2013).
RN   [59]
RP   INTERACTION WITH AMBRA1.
RX   PubMed=23524951; DOI=10.1038/ncb2708;
RA   Nazio F., Strappazzon F., Antonioli M., Bielli P., Cianfanelli V.,
RA   Bordi M., Gretzmeier C., Dengjel J., Piacentini M., Fimia G.M., Cecconi F.;
RT   "mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self-
RT   association and function through AMBRA1 and TRAF6.";
RL   Nat. Cell Biol. 15:406-416(2013).
RN   [60]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   CYS-70.
RX   PubMed=23514740; DOI=10.4049/jimmunol.1202742;
RA   Xie J.J., Liang J.Q., Diao L.H., Altman A., Li Y.;
RT   "TNFR-associated factor 6 regulates TCR signaling via interaction with and
RT   modification of LAT adapter.";
RL   J. Immunol. 190:4027-4036(2013).
RN   [61]
RP   SUBCELLULAR LOCATION, AND DEUBIQUITINATION BY EPSTEIN-BARR VIRUS PROTEIN
RP   BPLF1 (MICROBIAL INFECTION).
RX   PubMed=24586164; DOI=10.1371/journal.ppat.1003960;
RA   van Gent M., Braem S.G., de Jong A., Delagic N., Peeters J.G., Boer I.G.,
RA   Moynagh P.N., Kremmer E., Wiertz E.J., Ovaa H., Griffin B.D., Ressing M.E.;
RT   "Epstein-Barr virus large tegument protein BPLF1 contributes to innate
RT   immune evasion through interference with toll-like receptor signaling.";
RL   PLoS Pathog. 10:e1003960-e1003960(2014).
RN   [62]
RP   UBIQUITINATION, AND INTERACTION WITH LRRC19.
RX   PubMed=25026888; DOI=10.1038/ncomms5434;
RA   Su X., Min S., Cao S., Yan H., Zhao Y., Li H., Chai L., Mei S., Yang J.,
RA   Zhang Y., Zhang Z., Liu F., Sun W., Che Y., Yang R.;
RT   "LRRC19 expressed in the kidney induces TRAF2/6-mediated signals to prevent
RT   infection by uropathogenic bacteria.";
RL   Nat. Commun. 5:4434-4434(2014).
RN   [63]
RP   FUNCTION.
RX   PubMed=25907557; DOI=10.1074/jbc.m115.646422;
RA   Yang Y., Wu S., Wang Y., Pan S., Lan B., Liu Y., Zhang L., Leng Q.,
RA   Chen D., Zhang C., He B., Cao Y.;
RT   "The Us3 Protein of Herpes Simplex Virus 1 Inhibits T Cell Signaling by
RT   Confining Linker for Activation of T Cells (LAT) Activation via TRAF6
RT   Protein.";
RL   J. Biol. Chem. 290:15670-15678(2015).
RN   [64]
RP   INTERACTION WITH TICAM1.
RX   PubMed=25736436; DOI=10.15252/embr.201439637;
RA   Hu Y.H., Zhang Y., Jiang L.Q., Wang S., Lei C.Q., Sun M.S., Shu H.B.,
RA   Liu Y.;
RT   "WDFY1 mediates TLR3/4 signaling by recruiting TRIF.";
RL   EMBO Rep. 16:447-455(2015).
RN   [65]
RP   INTERACTION WITH TANK; USP10 AND ZC3H12A, AND DEUBIQUITINATION BY USP10.
RX   PubMed=25861989; DOI=10.1074/jbc.m115.643767;
RA   Wang W., Huang X., Xin H.B., Fu M., Xue A., Wu Z.H.;
RT   "TRAF family member-associated NF-kappaB activator (TANK) inhibits
RT   genotoxic nuclear factor kappaB activation by facilitating deubiquitinase
RT   USP10-dependent deubiquitination of TRAF6 ligase.";
RL   J. Biol. Chem. 290:13372-13385(2015).
RN   [66]
RP   FUNCTION, CATALYTIC ACTIVITY, PATHWAY, AND MUTAGENESIS OF CYS-70.
RX   PubMed=27746020; DOI=10.1016/j.molcel.2016.09.014;
RA   Ohtake F., Saeki Y., Ishido S., Kanno J., Tanaka K.;
RT   "The K48-K63 branched ubiquitin chain regulates NF-kappaB signaling.";
RL   Mol. Cell 64:251-266(2016).
RN   [67]
RP   INTERACTION WITH TRIM13.
RX   PubMed=28087809; DOI=10.1124/mol.116.106716;
RA   Huang B., Baek S.H.;
RT   "Trim13 potentiates toll-like receptor 2-mediated nuclear factor kappaB
RT   activation via K29-linked polyubiquitination of tumor necrosis factor
RT   receptor-associated factor 6.";
RL   Mol. Pharmacol. 91:307-316(2017).
RN   [68]
RP   FUNCTION, AND INTERACTION WITH CRBN.
RX   PubMed=31620128; DOI=10.3389/fimmu.2019.02203;
RA   Kim M.J., Min Y., Shim J.H., Chun E., Lee K.Y.;
RT   "CRBN Is a Negative Regulator of Bactericidal Activity and Autophagy
RT   Activation Through Inhibiting the Ubiquitination of ECSIT and BECN1.";
RL   Front. Immunol. 10:2203-2203(2019).
RN   [69]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 347-506 OF APOPROTEIN AND IN
RP   COMPLEXES WITH TNFRSF5 AND TNFRSF11A PEPTIDES, FUNCTION, AND SUBUNIT.
RX   PubMed=12140561; DOI=10.1038/nature00888;
RA   Ye H., Arron J.R., Lamothe B., Cirilli M., Kobayashi T., Shevde N.K.,
RA   Segal D., Dzivenu O.K., Vologodskaia M., Yim M., Du K., Singh S.,
RA   Pike J.W., Darnay B.G., Choi Y., Wu H.;
RT   "Distinct molecular mechanism for initiating TRAF6 signalling.";
RL   Nature 418:443-447(2002).
RN   [70]
RP   STRUCTURE BY NMR OF 63-124 IN COMPLEX WITH ZINC IONS, AND INTERACTION WITH
RP   UBE2N.
RX   PubMed=17327397; DOI=10.1110/ps.062358007;
RA   Mercier P., Lewis M.J., Hau D.D., Saltibus L.F., Xiao W., Spyracopoulos L.;
RT   "Structure, interactions, and dynamics of the RING domain from human
RT   TRAF6.";
RL   Protein Sci. 16:602-614(2007).
RN   [71]
RP   STRUCTURE BY NMR OF 43-128.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the RING domain of the human TNF receptor-associated
RT   factor 6 protein.";
RL   Submitted (MAR-2008) to the PDB data bank.
RN   [72]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 50-211 IN COMPLEXES WITH ZINC IONS
RP   AND UBE2N, SUBUNIT, FUNCTION, AUTOUBIQUITINATION, MUTAGENESIS OF ASP-57;
RP   CYS-70; ILE-72; LEU-74; ARG-88; PHE-118; PHE-122 AND LYS-124, AND
RP   ZINC-FINGER.
RX   PubMed=19465916; DOI=10.1038/nsmb.1605;
RA   Yin Q., Lin S.C., Lamothe B., Lu M., Lo Y.C., Hura G., Zheng L., Rich R.L.,
RA   Campos A.D., Myszka D.G., Lenardo M.J., Darnay B.G., Wu H.;
RT   "E2 interaction and dimerization in the crystal structure of TRAF6.";
RL   Nat. Struct. Mol. Biol. 16:658-666(2009).
CC   -!- FUNCTION: E3 ubiquitin ligase that, together with UBE2N and UBE2V1,
CC       mediates the synthesis of 'Lys-63'-linked-polyubiquitin chains
CC       conjugated to proteins, such as ECSIT, IKBKG, IRAK1, AKT1 and AKT2
CC       (PubMed:11057907, PubMed:18347055, PubMed:19465916, PubMed:19713527,
CC       PubMed:27746020, PubMed:31620128). Also mediates ubiquitination of
CC       free/unanchored polyubiquitin chain that leads to MAP3K7 activation
CC       (PubMed:19675569). Leads to the activation of NF-kappa-B and JUN
CC       (PubMed:16378096, PubMed:17135271, PubMed:17703191). Seems to also play
CC       a role in dendritic cells (DCs) maturation and/or activation (By
CC       similarity). Represses c-Myb-mediated transactivation, in B-lymphocytes
CC       (PubMed:18093978, PubMed:18758450). Adapter protein that seems to play
CC       a role in signal transduction initiated via TNF receptor, IL-1 receptor
CC       and IL-17 receptor (PubMed:12140561, PubMed:19825828, PubMed:8837778).
CC       Regulates osteoclast differentiation by mediating the activation of
CC       adapter protein complex 1 (AP-1) and NF-kappa-B, in response to RANK-L
CC       stimulation (By similarity). Together with MAP3K8, mediates CD40
CC       signals that activate ERK in B-cells and macrophages, and thus may play
CC       a role in the regulation of immunoglobulin production (By similarity).
CC       Acts as a regulator of the JNK and NF-kappa-B signaling pathways by
CC       initiating assembly of heterotypic 'Lys-63'-/'Lys-48'-linked branched
CC       ubiquitin chains that are then recognized by TAB2: TRAF6 catalyzes
CC       initial 'Lys-63'-linked-polyubiquitin chains that are then branched via
CC       'Lys-48'-linked polyubiquitin by HUWE1 (PubMed:27746020). 'Lys-
CC       63'-/'Lys-48'-linked branched ubiquitin chains protect 'Lys-63'-
CC       linkages from CYLD deubiquitination (PubMed:27746020). Participates
CC       also in the TCR signaling by ubiquitinating LAT (PubMed:23514740,
CC       PubMed:25907557). {ECO:0000250|UniProtKB:P70196,
CC       ECO:0000269|PubMed:11057907, ECO:0000269|PubMed:12140561,
CC       ECO:0000269|PubMed:16378096, ECO:0000269|PubMed:17135271,
CC       ECO:0000269|PubMed:17703191, ECO:0000269|PubMed:18093978,
CC       ECO:0000269|PubMed:18347055, ECO:0000269|PubMed:18758450,
CC       ECO:0000269|PubMed:19465916, ECO:0000269|PubMed:19675569,
CC       ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:19825828,
CC       ECO:0000269|PubMed:23514740, ECO:0000269|PubMed:25907557,
CC       ECO:0000269|PubMed:27746020, ECO:0000269|PubMed:31620128,
CC       ECO:0000269|PubMed:8837778}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine +
CC         [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-
CC         cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.;
CC         EC=2.3.2.27; Evidence={ECO:0000269|PubMed:17135271,
CC         ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:23514740,
CC         ECO:0000269|PubMed:27746020};
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000269|PubMed:23514740, ECO:0000269|PubMed:27746020}.
CC   -!- SUBUNIT: Homotrimer. Homooligomer. N-terminal region is dimeric while
CC       C-terminal region is trimeric; maybe providing a mode of
CC       oligomerization. Upon IL1B treatment, forms a complex with PELI1,
CC       IRAK1, IRAK4 and MYD88; this complex recruits MAP3K7/TAK1, TAB1 and
CC       TAB2 to mediate NF-kappa-B activation. Direct binding of SMAD6 to PELI1
CC       prevents the complex formation and hence negatively regulates IL1R-TLR
CC       signaling and eventually NF-kappa-B-mediated gene expression. Binds to
CC       TNFRSF5/CD40 and TNFRSF11A/RANK. Associates with NGFR, TNFRSF17, IRAK2,
CC       IRAK3, RIPK2, MAP3K1, MAP3K5, MAP3K14, CSK, TRAF, TRAF-interacting
CC       protein TRIP and TNF receptor associated protein TDP2. Interacts with
CC       IL17R. Interacts with SQSTM1 bridging NTRK1 and NGFR. Forms a ternary
CC       complex with SQSTM1 and PRKCZ (By similarity). Interacts with PELI2 and
CC       PELI3. Binds UBE2V1. Interacts with TAX1BP1; this interaction mediates
CC       deubiquitination of TRAF6 and inhibition of NF-kappa-B activation
CC       (PubMed:10920205, PubMed:17703191). Interacts with ZNF675. Interacts
CC       with ARRB1 and ARRB2. Interacts with MAP3K7 and TAB1/MAP3K7IP1; during
CC       IL-1 signaling. Interacts with UBE2N. Interacts with TGFBR1, HDAC1 and
CC       RANGAP1. Interacts with AKT1, AKT2 and AKT3. Interacts (via TRAF
CC       domains) with NUMBL (via C-terminal). Interacts with RBCK1. Interacts
CC       with LIMD1 (via LIM domains) (By similarity). Interacts with
CC       RSAD2/viperin (By similarity). Interacts (via C-terminus) with
CC       EIF2AK2/PKR (via the kinase catalytic domain) (By similarity).
CC       Interacts with ZFAND5. Interacts with IL1RL1. Interacts with TRAFD1.
CC       Interacts with AJUBA. Interacts with MAVS/IPS1. Interacts (via TRAF
CC       domains) with DYNC2I2 (via WD domains). Interacts with IFIT3 (via N-
CC       terminus). Interacts with TICAM2. Interacts with CARD14. Interacts with
CC       CD40 and MAP3K8; the interaction is required for ERK activation (By
CC       similarity). Interacts with TICAM1 and this interaction is enhanced in
CC       the presence of WDFY1 (PubMed:25736436). Interacts with TANK; this
CC       interaction increases in response to DNA damage (PubMed:25861989).
CC       Interacts with USP10; this interaction increases in response to DNA
CC       damage (PubMed:25861989). Interacts with ZC3H12A; this interaction
CC       increases in response to DNA damage and is stimulated by TANK
CC       (PubMed:25861989). Interacts with WDFY3 (By similarity). Interacts with
CC       TRIM13 (PubMed:28087809). Interacts with GPS2 (By similarity).
CC       Interacts (via C-terminus) with SASH1 (PubMed:23776175). Interacts with
CC       LRRC19 (PubMed:25026888). Interacts with IL17RA and TRAF3IP2. Interacts
CC       with TOMM70 (PubMed:20628368). Interacts with AMBRA1; interaction is
CC       required to mediate 'Lys-63'-linked ubiquitination of ULK1
CC       (PubMed:23524951). Interacts with CRBN; this interaction inhibits TLR4-
CC       mediated signaling by preventing TRAF6-mediated ubiquitination of ECSIT
CC       (PubMed:31620128). {ECO:0000250|UniProtKB:P70196,
CC       ECO:0000269|PubMed:10920205, ECO:0000269|PubMed:17703191,
CC       ECO:0000269|PubMed:19825828, ECO:0000269|PubMed:20628368,
CC       ECO:0000269|PubMed:23524951, ECO:0000269|PubMed:23776175,
CC       ECO:0000269|PubMed:25026888, ECO:0000269|PubMed:25736436,
CC       ECO:0000269|PubMed:25861989, ECO:0000269|PubMed:28087809,
CC       ECO:0000269|PubMed:31620128}.
CC   -!- INTERACTION:
CC       Q9Y4K3; Q9C0C7-3: AMBRA1; NbExp=2; IntAct=EBI-359276, EBI-16042318;
CC       Q9Y4K3; Q8IWQ3-3: BRSK2; NbExp=3; IntAct=EBI-359276, EBI-13085322;
CC       Q9Y4K3; P25942: CD40; NbExp=2; IntAct=EBI-359276, EBI-525714;
CC       Q9Y4K3; Q9HAV5: EDA2R; NbExp=3; IntAct=EBI-359276, EBI-526033;
CC       Q9Y4K3; Q8WWZ3: EDARADD; NbExp=5; IntAct=EBI-359276, EBI-2949647;
CC       Q9Y4K3; P14778: IL1R1; NbExp=2; IntAct=EBI-359276, EBI-525905;
CC       Q9Y4K3; Q8NA54: IQUB; NbExp=3; IntAct=EBI-359276, EBI-10220600;
CC       Q9Y4K3; P51617: IRAK1; NbExp=3; IntAct=EBI-359276, EBI-358664;
CC       Q9Y4K3; O43187: IRAK2; NbExp=4; IntAct=EBI-359276, EBI-447733;
CC       Q9Y4K3; Q9Y616: IRAK3; NbExp=3; IntAct=EBI-359276, EBI-447690;
CC       Q9Y4K3; Q8TBB1: LNX1; NbExp=3; IntAct=EBI-359276, EBI-739832;
CC       Q9Y4K3; Q9UDY8: MALT1; NbExp=5; IntAct=EBI-359276, EBI-1047372;
CC       Q9Y4K3; O43318: MAP3K7; NbExp=2; IntAct=EBI-359276, EBI-358684;
CC       Q9Y4K3; Q7Z434: MAVS; NbExp=4; IntAct=EBI-359276, EBI-995373;
CC       Q9Y4K3; P50222: MEOX2; NbExp=3; IntAct=EBI-359276, EBI-748397;
CC       Q9Y4K3; Q8N3F0: MTURN; NbExp=3; IntAct=EBI-359276, EBI-11980301;
CC       Q9Y4K3; Q96DC9: OTUB2; NbExp=3; IntAct=EBI-359276, EBI-746259;
CC       Q9Y4K3; Q9H8W4: PLEKHF2; NbExp=3; IntAct=EBI-359276, EBI-742388;
CC       Q9Y4K3; Q9UNA4: POLI; NbExp=3; IntAct=EBI-359276, EBI-741774;
CC       Q9Y4K3; P54725: RAD23A; NbExp=3; IntAct=EBI-359276, EBI-746453;
CC       Q9Y4K3; Q9BVN2-2: RUSC1; NbExp=2; IntAct=EBI-359276, EBI-6257338;
CC       Q9Y4K3; P04271: S100B; NbExp=3; IntAct=EBI-359276, EBI-458391;
CC       Q9Y4K3; Q9NYA1: SPHK1; NbExp=2; IntAct=EBI-359276, EBI-985303;
CC       Q9Y4K3; Q13501: SQSTM1; NbExp=4; IntAct=EBI-359276, EBI-307104;
CC       Q9Y4K3; P43405-2: SYK; NbExp=3; IntAct=EBI-359276, EBI-25892332;
CC       Q9Y4K3; Q9NYJ8: TAB2; NbExp=3; IntAct=EBI-359276, EBI-358708;
CC       Q9Y4K3; Q86VP1: TAX1BP1; NbExp=8; IntAct=EBI-359276, EBI-529518;
CC       Q9Y4K3; Q96CG3: TIFA; NbExp=6; IntAct=EBI-359276, EBI-740711;
CC       Q9Y4K3; Q9UKE5: TNIK; NbExp=3; IntAct=EBI-359276, EBI-1051794;
CC       Q9Y4K3; Q13077: TRAF1; NbExp=20; IntAct=EBI-359276, EBI-359224;
CC       Q9Y4K3; Q12933: TRAF2; NbExp=10; IntAct=EBI-359276, EBI-355744;
CC       Q9Y4K3; O43734: TRAF3IP2; NbExp=4; IntAct=EBI-359276, EBI-744798;
CC       Q9Y4K3; O00463: TRAF5; NbExp=15; IntAct=EBI-359276, EBI-523498;
CC       Q9Y4K3; Q9Y4K3: TRAF6; NbExp=11; IntAct=EBI-359276, EBI-359276;
CC       Q9Y4K3; P0CG48: UBC; NbExp=3; IntAct=EBI-359276, EBI-3390054;
CC       Q9Y4K3; P51668: UBE2D1; NbExp=2; IntAct=EBI-359276, EBI-743540;
CC       Q9Y4K3; P62837: UBE2D2; NbExp=5; IntAct=EBI-359276, EBI-347677;
CC       Q9Y4K3; P61077: UBE2D3; NbExp=2; IntAct=EBI-359276, EBI-348268;
CC       Q9Y4K3; P61088: UBE2N; NbExp=8; IntAct=EBI-359276, EBI-1052908;
CC       Q9Y4K3; Q9HAC8: UBTD1; NbExp=3; IntAct=EBI-359276, EBI-745871;
CC       Q9Y4K3; O94888: UBXN7; NbExp=3; IntAct=EBI-359276, EBI-1993627;
CC       Q9Y4K3; P09936: UCHL1; NbExp=3; IntAct=EBI-359276, EBI-714860;
CC       Q9Y4K3; O75385: ULK1; NbExp=2; IntAct=EBI-359276, EBI-908831;
CC       Q9Y4K3; O75604: USP2; NbExp=3; IntAct=EBI-359276, EBI-743272;
CC       Q9Y4K3; Q8N1B4: VPS52; NbExp=6; IntAct=EBI-359276, EBI-2799833;
CC       Q9Y4K3; P61964: WDR5; NbExp=2; IntAct=EBI-359276, EBI-540834;
CC       Q9Y4K3; P07947: YES1; NbExp=6; IntAct=EBI-359276, EBI-515331;
CC       Q9Y4K3; Q5VVQ6: YOD1; NbExp=5; IntAct=EBI-359276, EBI-2510804;
CC       Q9Y4K3; P24278: ZBTB25; NbExp=3; IntAct=EBI-359276, EBI-739899;
CC       Q9Y4K3; Q8TD23: ZNF675; NbExp=4; IntAct=EBI-359276, EBI-528190;
CC       Q9Y4K3; Q9UGI0: ZRANB1; NbExp=4; IntAct=EBI-359276, EBI-527853;
CC       Q9Y4K3; Q9QZH6: Ecsit; Xeno; NbExp=2; IntAct=EBI-359276, EBI-527020;
CC       Q9Y4K3; P07174: Ngfr; Xeno; NbExp=2; IntAct=EBI-359276, EBI-1038810;
CC       Q9Y4K3; P10221: UL37; Xeno; NbExp=3; IntAct=EBI-359276, EBI-6880600;
CC       Q9Y4K3; Q01220: VACWR178; Xeno; NbExp=2; IntAct=EBI-359276, EBI-3863691;
CC       Q9Y4K3; Q8V2D1; Xeno; NbExp=3; IntAct=EBI-359276, EBI-8622036;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:18093978,
CC       ECO:0000269|PubMed:23514740, ECO:0000269|PubMed:24586164}. Cytoplasm,
CC       cell cortex {ECO:0000269|PubMed:18093978}. Nucleus
CC       {ECO:0000269|PubMed:18093978}. Lipid droplet
CC       {ECO:0000250|UniProtKB:P70196}. Note=Found in the nuclei of some
CC       aggressive B-cell lymphoma cell lines as well as in the nuclei of both
CC       resting and activated T- and B-lymphocytes. Found in punctate nuclear
CC       body protein complexes. Ubiquitination may occur in the cytoplasm and
CC       sumoylation in the nucleus. RSAD2/viperin recruits it to the lipid
CC       droplet (By similarity). {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Expressed in heart, brain, placenta, lung, liver,
CC       skeletal muscle, kidney and pancreas.
CC   -!- DOMAIN: The coiled coil domain mediates homo- and hetero-
CC       oligomerization.
CC   -!- DOMAIN: The MATH/TRAF domain binds to receptor cytoplasmic domains.
CC   -!- PTM: Sumoylated on Lys-124, Lys-142 and Lys-453 with SUMO1.
CC       {ECO:0000269|PubMed:18093978}.
CC   -!- PTM: Polyubiquitinated on Lys-124 by TRAF3IP2; after cell stimulation
CC       with IL17A (PubMed:19825828). Polyubiquitinated on Lys-124; after cell
CC       stimulation with IL1B or TGFB. This ligand-induced cell stimulation
CC       leads to dimerization/oligomerization of TRAF6 molecules, followed by
CC       auto-ubiquitination which involves UBE2N and UBE2V1 and leads to TRAF6
CC       activation. This 'Lys-63' site-specific poly-ubiquitination appears to
CC       be associated with the activation of signaling molecules. Endogenous
CC       autoubiquitination occurs only for the cytoplasmic form.
CC       Deubiquitinated by USP10 in a TANK-dependent manner, leading to the
CC       negative regulation of NF-kappaB signaling upon DNA damage
CC       (PubMed:25861989). LRRC19 induces 'Lys-63' ubiquitination
CC       (PubMed:25026888). Ubiquitinated at Lys-319 by the SCF(FBXL2) complex,
CC       leading to its degradation by the proteasome (By similarity).
CC       {ECO:0000250|UniProtKB:P70196, ECO:0000269|PubMed:11460167,
CC       ECO:0000269|PubMed:17135271, ECO:0000269|PubMed:18093978,
CC       ECO:0000269|PubMed:18758450, ECO:0000269|PubMed:19465916,
CC       ECO:0000269|PubMed:19675569, ECO:0000269|PubMed:19825828,
CC       ECO:0000269|PubMed:25026888, ECO:0000269|PubMed:25861989}.
CC   -!- PTM: (Microbial infection) Deubiquitinated by Epstein-Barr virus BPLF1
CC       on both 'Lys-48' and 'Lys-63'-linked ubiquitin chains; leading to NF-
CC       kappa-B signaling inhibition. {ECO:0000269|PubMed:24586164}.
CC   -!- SIMILARITY: Belongs to the TNF receptor-associated factor family. A
CC       subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U78798; AAB38751.1; -; mRNA.
DR   EMBL; AY228337; AAO38054.1; -; Genomic_DNA.
DR   EMBL; AK292978; BAF85667.1; -; mRNA.
DR   EMBL; AC009656; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC061999; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471064; EAW68119.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW68120.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW68122.1; -; Genomic_DNA.
DR   EMBL; BC031052; AAH31052.1; -; mRNA.
DR   CCDS; CCDS7901.1; -.
DR   PIR; S71821; S71821.
DR   RefSeq; NP_004611.1; NM_004620.4.
DR   RefSeq; NP_665802.1; NM_145803.3.
DR   PDB; 1LB4; X-ray; 2.40 A; A=348-504.
DR   PDB; 1LB5; X-ray; 2.40 A; A=347-504.
DR   PDB; 1LB6; X-ray; 1.80 A; A=347-504.
DR   PDB; 2ECI; NMR; -; A=50-128.
DR   PDB; 2JMD; NMR; -; A=67-124.
DR   PDB; 3HCS; X-ray; 2.20 A; A/B=50-211.
DR   PDB; 3HCT; X-ray; 2.10 A; A=50-159.
DR   PDB; 3HCU; X-ray; 2.60 A; A/C=50-159.
DR   PDB; 4Z8M; X-ray; 2.95 A; A/B=346-504.
DR   PDB; 5ZUJ; X-ray; 2.60 A; A=350-501.
DR   PDB; 6A33; X-ray; 2.10 A; A=350-501.
DR   PDB; 7L3L; X-ray; 2.80 A; B/D=52-158.
DR   PDB; 8HZ2; X-ray; 2.60 A; A/B=54-210.
DR   PDBsum; 1LB4; -.
DR   PDBsum; 1LB5; -.
DR   PDBsum; 1LB6; -.
DR   PDBsum; 2ECI; -.
DR   PDBsum; 2JMD; -.
DR   PDBsum; 3HCS; -.
DR   PDBsum; 3HCT; -.
DR   PDBsum; 3HCU; -.
DR   PDBsum; 4Z8M; -.
DR   PDBsum; 5ZUJ; -.
DR   PDBsum; 6A33; -.
DR   PDBsum; 7L3L; -.
DR   PDBsum; 8HZ2; -.
DR   AlphaFoldDB; Q9Y4K3; -.
DR   SMR; Q9Y4K3; -.
DR   BioGRID; 113041; 453.
DR   ComplexPortal; CPX-9621; TRAF6-TIFA E3 ubiquitin ligase complex.
DR   CORUM; Q9Y4K3; -.
DR   DIP; DIP-27515N; -.
DR   ELM; Q9Y4K3; -.
DR   FunCoup; Q9Y4K3; 3273.
DR   IntAct; Q9Y4K3; 130.
DR   MINT; Q9Y4K3; -.
DR   STRING; 9606.ENSP00000433623; -.
DR   BindingDB; Q9Y4K3; -.
DR   ChEMBL; CHEMBL3588728; -.
DR   MoonDB; Q9Y4K3; Predicted.
DR   GlyGen; Q9Y4K3; 1 site.
DR   iPTMnet; Q9Y4K3; -.
DR   PhosphoSitePlus; Q9Y4K3; -.
DR   BioMuta; TRAF6; -.
DR   DMDM; 30580642; -.
DR   jPOST; Q9Y4K3; -.
DR   MassIVE; Q9Y4K3; -.
DR   PaxDb; 9606-ENSP00000433623; -.
DR   PeptideAtlas; Q9Y4K3; -.
DR   ProteomicsDB; 86225; -.
DR   Pumba; Q9Y4K3; -.
DR   Antibodypedia; 3895; 560 antibodies from 45 providers.
DR   DNASU; 7189; -.
DR   Ensembl; ENST00000348124.5; ENSP00000337853.5; ENSG00000175104.15.
DR   Ensembl; ENST00000526995.6; ENSP00000433623.1; ENSG00000175104.15.
DR   GeneID; 7189; -.
DR   KEGG; hsa:7189; -.
DR   MANE-Select; ENST00000526995.6; ENSP00000433623.1; NM_004620.4; NP_004611.1.
DR   UCSC; uc001mwq.3; human.
DR   AGR; HGNC:12036; -.
DR   CTD; 7189; -.
DR   DisGeNET; 7189; -.
DR   GeneCards; TRAF6; -.
DR   HGNC; HGNC:12036; TRAF6.
DR   HPA; ENSG00000175104; Low tissue specificity.
DR   MalaCards; TRAF6; -.
DR   MIM; 602355; gene.
DR   neXtProt; NX_Q9Y4K3; -.
DR   OpenTargets; ENSG00000175104; -.
DR   Orphanet; 1810; Autosomal dominant hypohidrotic ectodermal dysplasia.
DR   PharmGKB; PA36713; -.
DR   VEuPathDB; HostDB:ENSG00000175104; -.
DR   eggNOG; KOG0297; Eukaryota.
DR   GeneTree; ENSGT00940000155426; -.
DR   HOGENOM; CLU_021061_5_0_1; -.
DR   InParanoid; Q9Y4K3; -.
DR   OMA; FMHLQAL; -.
DR   OrthoDB; 6475149at2759; -.
DR   PAN-GO; Q9Y4K3; 9 GO annotations based on evolutionary models.
DR   PhylomeDB; Q9Y4K3; -.
DR   TreeFam; TF321154; -.
DR   PathwayCommons; Q9Y4K3; -.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-166058; MyD88:MAL(TIRAP) cascade initiated on plasma membrane.
DR   Reactome; R-HSA-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-HSA-168927; TICAM1, RIP1-mediated IKK complex recruitment.
DR   Reactome; R-HSA-193692; Regulated proteolysis of p75NTR.
DR   Reactome; R-HSA-202424; Downstream TCR signaling.
DR   Reactome; R-HSA-205043; NRIF signals cell death from the nucleus.
DR   Reactome; R-HSA-209543; p75NTR recruits signalling complexes.
DR   Reactome; R-HSA-209560; NF-kB is activated and signals survival.
DR   Reactome; R-HSA-2871837; FCERI mediated NF-kB activation.
DR   Reactome; R-HSA-445989; TAK1-dependent IKK and NF-kappa-B activation.
DR   Reactome; R-HSA-450302; activated TAK1 mediates p38 MAPK activation.
DR   Reactome; R-HSA-450321; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1.
DR   Reactome; R-HSA-5607764; CLEC7A (Dectin-1) signaling.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-5689896; Ovarian tumor domain proteases.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-9014325; TICAM1,TRAF6-dependent induction of TAK1 complex.
DR   Reactome; R-HSA-9020702; Interleukin-1 signaling.
DR   Reactome; R-HSA-933541; TRAF6 mediated IRF7 activation.
DR   Reactome; R-HSA-933542; TRAF6 mediated NF-kB activation.
DR   Reactome; R-HSA-937039; IRAK1 recruits IKK complex.
DR   Reactome; R-HSA-937041; IKK complex recruitment mediated by RIP1.
DR   Reactome; R-HSA-937042; IRAK2 mediated activation of TAK1 complex.
DR   Reactome; R-HSA-937072; TRAF6-mediated induction of TAK1 complex within TLR4 complex.
DR   Reactome; R-HSA-9645460; Alpha-protein kinase 1 signaling pathway.
DR   Reactome; R-HSA-9692916; SARS-CoV-1 activates/modulates innate immune responses.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   Reactome; R-HSA-975110; TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling.
DR   Reactome; R-HSA-975138; TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation.
DR   Reactome; R-HSA-975144; IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation.
DR   Reactome; R-HSA-975155; MyD88 dependent cascade initiated on endosome.
DR   Reactome; R-HSA-975163; IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation.
DR   Reactome; R-HSA-9758274; Regulation of NF-kappa B signaling.
DR   Reactome; R-HSA-975871; MyD88 cascade initiated on plasma membrane.
DR   SignaLink; Q9Y4K3; -.
DR   SIGNOR; Q9Y4K3; -.
DR   UniPathway; UPA00143; -.
DR   BioGRID-ORCS; 7189; 38 hits in 1201 CRISPR screens.
DR   ChiTaRS; TRAF6; human.
DR   EvolutionaryTrace; Q9Y4K3; -.
DR   GeneWiki; TRAF6; -.
DR   GenomeRNAi; 7189; -.
DR   Pharos; Q9Y4K3; Tbio.
DR   PRO; PR:Q9Y4K3; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q9Y4K3; protein.
DR   Bgee; ENSG00000175104; Expressed in secondary oocyte and 158 other cell types or tissues.
DR   GO; GO:0035631; C:CD40 receptor complex; ISS:BHF-UCL.
DR   GO; GO:0005938; C:cell cortex; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; ISS:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0010008; C:endosome membrane; TAS:Reactome.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IC:UniProt.
DR   GO; GO:0098978; C:glutamatergic synapse; IBA:GO_Central.
DR   GO; GO:0005811; C:lipid droplet; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IDA:MGI.
DR   GO; GO:0042826; F:histone deacetylase binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0043422; F:protein kinase B binding; IPI:UniProtKB.
DR   GO; GO:0030674; F:protein-macromolecule adaptor activity; IDA:UniProt.
DR   GO; GO:0035591; F:signaling adaptor activity; IBA:GO_Central.
DR   GO; GO:0005164; F:tumor necrosis factor receptor binding; IEA:InterPro.
DR   GO; GO:0031624; F:ubiquitin conjugating enzyme binding; IDA:MGI.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:UniProtKB.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; EXP:Reactome.
DR   GO; GO:0034450; F:ubiquitin-ubiquitin ligase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0032147; P:activation of protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0019886; P:antigen processing and presentation of exogenous peptide antigen via MHC class II; IEA:Ensembl.
DR   GO; GO:0140374; P:antiviral innate immune response; IDA:UniProt.
DR   GO; GO:0000045; P:autophagosome assembly; IDA:UniProt.
DR   GO; GO:0045453; P:bone resorption; IEA:Ensembl.
DR   GO; GO:0007249; P:canonical NF-kappaB signal transduction; IDA:UniProt.
DR   GO; GO:0023035; P:CD40 signaling pathway; IDA:UniProt.
DR   GO; GO:0071345; P:cellular response to cytokine stimulus; IMP:ARUK-UCL.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IDA:MGI.
DR   GO; GO:0002753; P:cytoplasmic pattern recognition receptor signaling pathway; IDA:UniProt.
DR   GO; GO:0006974; P:DNA damage response; IEA:UniProtKB-KW.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0070498; P:interleukin-1-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0097400; P:interleukin-17-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0038173; P:interleukin-17A-mediated signaling pathway; IDA:UniProt.
DR   GO; GO:0038172; P:interleukin-33-mediated signaling pathway; IMP:UniProt.
DR   GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IBA:GO_Central.
DR   GO; GO:0002755; P:MyD88-dependent toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0043011; P:myeloid dendritic cell differentiation; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IMP:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IMP:UniProtKB.
DR   GO; GO:0001843; P:neural tube closure; IEA:Ensembl.
DR   GO; GO:0038061; P:non-canonical NF-kappaB signal transduction; IDA:UniProt.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0001503; P:ossification; IEA:UniProtKB-KW.
DR   GO; GO:0030316; P:osteoclast differentiation; IEA:Ensembl.
DR   GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; IDA:UniProtKB.
DR   GO; GO:0032735; P:positive regulation of interleukin-12 production; IEA:Ensembl.
DR   GO; GO:0032743; P:positive regulation of interleukin-2 production; IMP:UniProtKB.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IEA:Ensembl.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IDA:BHF-UCL.
DR   GO; GO:0043507; P:positive regulation of JUN kinase activity; NAS:UniProtKB.
DR   GO; GO:1904996; P:positive regulation of leukocyte adhesion to vascular endothelial cell; IMP:ARUK-UCL.
DR   GO; GO:0031666; P:positive regulation of lipopolysaccharide-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0045672; P:positive regulation of osteoclast differentiation; IDA:UniProtKB.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; NAS:BHF-UCL.
DR   GO; GO:0002726; P:positive regulation of T cell cytokine production; IMP:UniProtKB.
DR   GO; GO:0042102; P:positive regulation of T cell proliferation; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0032481; P:positive regulation of type I interferon production; IEA:Ensembl.
DR   GO; GO:0051865; P:protein autoubiquitination; IDA:UniProtKB.
DR   GO; GO:0141198; P:protein branched polyubiquitination; IDA:UniProtKB.
DR   GO; GO:0070534; P:protein K63-linked ubiquitination; IDA:UniProtKB.
DR   GO; GO:0000209; P:protein polyubiquitination; IDA:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; IEA:InterPro.
DR   GO; GO:0043122; P:regulation of canonical NF-kappaB signal transduction; IBA:GO_Central.
DR   GO; GO:0002637; P:regulation of immunoglobulin production; IEA:Ensembl.
DR   GO; GO:0098696; P:regulation of neurotransmitter receptor localization to postsynaptic specialization membrane; IEA:Ensembl.
DR   GO; GO:0070555; P:response to interleukin-1; IDA:UniProtKB.
DR   GO; GO:0002223; P:stimulatory C-type lectin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; IDA:UniProt.
DR   GO; GO:0042088; P:T-helper 1 type immune response; IEA:Ensembl.
DR   GO; GO:0034138; P:toll-like receptor 3 signaling pathway; TAS:Reactome.
DR   GO; GO:0034142; P:toll-like receptor 4 signaling pathway; IDA:UniProt.
DR   GO; GO:0035666; P:TRIF-dependent toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; IMP:BHF-UCL.
DR   CDD; cd03776; MATH_TRAF6; 1.
DR   CDD; cd16643; mRING-HC-C3HC3D_TRAF6; 1.
DR   FunFam; 2.60.210.10:FF:000010; TNF receptor-associated factor; 1.
DR   FunFam; 3.30.40.10:FF:000179; TNF receptor-associated factor; 1.
DR   FunFam; 3.30.40.10:FF:000211; TNF receptor-associated factor; 1.
DR   FunFam; 3.30.40.10:FF:000289; TNF receptor-associated factor; 1.
DR   Gene3D; 2.60.210.10; Apoptosis, Tumor Necrosis Factor Receptor Associated Protein 2, Chain A; 1.
DR   Gene3D; 3.30.40.10; Zinc/RING finger domain, C3HC4 (zinc finger); 3.
DR   IDEAL; IID00744; -.
DR   InterPro; IPR002083; MATH/TRAF_dom.
DR   InterPro; IPR012227; TNF_rcpt-assoc_TRAF_met.
DR   InterPro; IPR008974; TRAF-like.
DR   InterPro; IPR049342; TRAF1-6_MATH_dom.
DR   InterPro; IPR037309; TRAF6_MATH.
DR   InterPro; IPR027139; TRAF6_RING-HC.
DR   InterPro; IPR041310; TRAF6_Z2.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   InterPro; IPR001293; Znf_TRAF.
DR   PANTHER; PTHR10131; TNF RECEPTOR ASSOCIATED FACTOR; 1.
DR   PANTHER; PTHR10131:SF152; TNF RECEPTOR-ASSOCIATED FACTOR 6; 1.
DR   Pfam; PF21355; TRAF-mep_MATH; 1.
DR   Pfam; PF18048; TRAF6_Z2; 1.
DR   Pfam; PF13923; zf-C3HC4_2; 1.
DR   Pfam; PF02176; zf-TRAF; 1.
DR   PIRSF; PIRSF015614; TRAF; 1.
DR   SMART; SM00061; MATH; 1.
DR   SMART; SM00184; RING; 1.
DR   SUPFAM; SSF57850; RING/U-box; 1.
DR   SUPFAM; SSF49599; TRAF domain-like; 3.
DR   PROSITE; PS50144; MATH; 1.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
DR   PROSITE; PS50145; ZF_TRAF; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Coiled coil; Cytoplasm; DNA damage; Immunity;
KW   Isopeptide bond; Lipid droplet; Metal-binding; Nucleus; Osteogenesis;
KW   Proteomics identification; Reference proteome; Repeat; Transferase;
KW   Ubl conjugation; Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN           1..522
FT                   /note="TNF receptor-associated factor 6"
FT                   /id="PRO_0000056407"
FT   DOMAIN          350..499
FT                   /note="MATH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00129"
FT   ZN_FING         70..109
FT                   /note="RING-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00175"
FT   ZN_FING         150..202
FT                   /note="TRAF-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00207"
FT   ZN_FING         203..259
FT                   /note="TRAF-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00207"
FT   REGION          1..354
FT                   /note="Interaction with TAX1BP1"
FT                   /evidence="ECO:0000269|PubMed:10920205"
FT   REGION          355..522
FT                   /note="Interaction with TANK"
FT                   /evidence="ECO:0000269|PubMed:25861989"
FT   COILED          288..348
FT                   /evidence="ECO:0000255"
FT   CROSSLNK        124
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT   CROSSLNK        124
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin); alternate"
FT                   /evidence="ECO:0000269|PubMed:17135271,
FT                   ECO:0000269|PubMed:19825828"
FT   CROSSLNK        142
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000269|PubMed:18093978"
FT   CROSSLNK        319
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:P70196"
FT   CROSSLNK        453
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000269|PubMed:18093978"
FT   MUTAGEN         57
FT                   /note="D->K: Loss of interaction with UBE2N."
FT                   /evidence="ECO:0000269|PubMed:19465916"
FT   MUTAGEN         70
FT                   /note="C->A: Loss of ligase activity, autoubiquitination
FT                   and signaling capacity."
FT                   /evidence="ECO:0000269|PubMed:17135271,
FT                   ECO:0000269|PubMed:19465916, ECO:0000269|PubMed:23514740,
FT                   ECO:0000269|PubMed:27746020"
FT   MUTAGEN         72
FT                   /note="I->D: Loss of interaction with UBE2N. Has no effect
FT                   on TRAF3IP2-mediated 'Lys-63'-linked polyubiquitination."
FT                   /evidence="ECO:0000269|PubMed:19465916,
FT                   ECO:0000269|PubMed:19825828"
FT   MUTAGEN         74
FT                   /note="L->E,K: Loss of interaction with UBE2N."
FT                   /evidence="ECO:0000269|PubMed:19465916"
FT   MUTAGEN         88
FT                   /note="R->A: Loss of TRAF6 homodimerization and impaired
FT                   polyubiquitin synthesis. Loss of TRAF6 homodimerization and
FT                   impaired polyubiquitin synthesis; when associated with
FT                   A-122."
FT                   /evidence="ECO:0000269|PubMed:19465916"
FT   MUTAGEN         118
FT                   /note="F->A: Loss of TRAF6 homodimerization and impaired
FT                   polyubiquitin synthesis."
FT                   /evidence="ECO:0000269|PubMed:19465916"
FT   MUTAGEN         118
FT                   /note="F->W: Partially impaired polyubiquitin synthesis."
FT                   /evidence="ECO:0000269|PubMed:19465916"
FT   MUTAGEN         118
FT                   /note="F->Y: Partially impaired polyubiquitin synthesis."
FT                   /evidence="ECO:0000269|PubMed:19465916"
FT   MUTAGEN         122
FT                   /note="F->A: Loss of TRAF6 homodimerization and partially
FT                   impaired polyubiquitin synthesis. Loss of TRAF6
FT                   homodimerization and impaired polyubiquitin synthesis; when
FT                   associated with A-88."
FT                   /evidence="ECO:0000269|PubMed:19465916"
FT   MUTAGEN         124
FT                   /note="K->R: Loss of SUMO1-modification and c-myb-mediated
FT                   transcriptional repressive activation. Loss of
FT                   TRAF3IP2-mediated 'Lys-63'-linked polyubiquitination."
FT                   /evidence="ECO:0000269|PubMed:17135271,
FT                   ECO:0000269|PubMed:18093978, ECO:0000269|PubMed:19465916,
FT                   ECO:0000269|PubMed:19825828"
FT   MUTAGEN         142
FT                   /note="K->R: Loss of SUMO1-modification and c-myb-mediated
FT                   transcriptional repressive activation."
FT                   /evidence="ECO:0000269|PubMed:18093978"
FT   MUTAGEN         453
FT                   /note="K->R: Loss of SUMO1-modification and c-myb-mediated
FT                   transcriptional repressive activation."
FT                   /evidence="ECO:0000269|PubMed:18093978"
FT   CONFLICT        12
FT                   /note="S -> F (in Ref. 6; AAH31052)"
FT                   /evidence="ECO:0000305"
FT   STRAND          60..62
FT                   /evidence="ECO:0007829|PDB:3HCT"
FT   HELIX           66..68
FT                   /evidence="ECO:0007829|PDB:3HCT"
FT   TURN            71..73
FT                   /evidence="ECO:0007829|PDB:3HCT"
FT   STRAND          74..76
FT                   /evidence="ECO:0007829|PDB:8HZ2"
FT   STRAND          78..82
FT                   /evidence="ECO:0007829|PDB:3HCT"
FT   TURN            84..86
FT                   /evidence="ECO:0007829|PDB:2ECI"
FT   STRAND          88..90
FT                   /evidence="ECO:0007829|PDB:3HCT"
FT   HELIX           91..101
FT                   /evidence="ECO:0007829|PDB:3HCT"
FT   TURN            106..108
FT                   /evidence="ECO:0007829|PDB:3HCT"
FT   HELIX           114..116
FT                   /evidence="ECO:0007829|PDB:3HCT"
FT   HELIX           121..128
FT                   /evidence="ECO:0007829|PDB:3HCT"
FT   STRAND          130..133
FT                   /evidence="ECO:0007829|PDB:3HCT"
FT   STRAND          135..138
FT                   /evidence="ECO:0007829|PDB:3HCU"
FT   STRAND          142..144
FT                   /evidence="ECO:0007829|PDB:3HCT"
FT   HELIX           145..147
FT                   /evidence="ECO:0007829|PDB:3HCT"
FT   HELIX           149..151
FT                   /evidence="ECO:0007829|PDB:3HCT"
FT   STRAND          153..155
FT                   /evidence="ECO:0007829|PDB:3HCT"
FT   STRAND          158..161
FT                   /evidence="ECO:0007829|PDB:3HCS"
FT   TURN            163..165
FT                   /evidence="ECO:0007829|PDB:3HCS"
FT   STRAND          168..170
FT                   /evidence="ECO:0007829|PDB:3HCS"
FT   HELIX           171..173
FT                   /evidence="ECO:0007829|PDB:3HCS"
FT   HELIX           174..180
FT                   /evidence="ECO:0007829|PDB:3HCS"
FT   STRAND          186..188
FT                   /evidence="ECO:0007829|PDB:3HCS"
FT   TURN            190..192
FT                   /evidence="ECO:0007829|PDB:3HCS"
FT   STRAND          195..197
FT                   /evidence="ECO:0007829|PDB:3HCS"
FT   HELIX           198..200
FT                   /evidence="ECO:0007829|PDB:3HCS"
FT   HELIX           201..205
FT                   /evidence="ECO:0007829|PDB:3HCS"
FT   STRAND          351..357
FT                   /evidence="ECO:0007829|PDB:1LB6"
FT   HELIX           360..368
FT                   /evidence="ECO:0007829|PDB:1LB6"
FT   STRAND          373..376
FT                   /evidence="ECO:0007829|PDB:1LB6"
FT   STRAND          380..385
FT                   /evidence="ECO:0007829|PDB:1LB6"
FT   STRAND          388..395
FT                   /evidence="ECO:0007829|PDB:1LB6"
FT   TURN            401..405
FT                   /evidence="ECO:0007829|PDB:1LB6"
FT   STRAND          406..414
FT                   /evidence="ECO:0007829|PDB:1LB6"
FT   HELIX           419..421
FT                   /evidence="ECO:0007829|PDB:1LB6"
FT   STRAND          428..434
FT                   /evidence="ECO:0007829|PDB:1LB6"
FT   HELIX           440..442
FT                   /evidence="ECO:0007829|PDB:6A33"
FT   STRAND          446..451
FT                   /evidence="ECO:0007829|PDB:1LB6"
FT   HELIX           457..459
FT                   /evidence="ECO:0007829|PDB:1LB6"
FT   STRAND          463..466
FT                   /evidence="ECO:0007829|PDB:1LB6"
FT   STRAND          468..478
FT                   /evidence="ECO:0007829|PDB:1LB6"
FT   HELIX           479..483
FT                   /evidence="ECO:0007829|PDB:1LB6"
FT   TURN            484..486
FT                   /evidence="ECO:0007829|PDB:6A33"
FT   STRAND          492..500
FT                   /evidence="ECO:0007829|PDB:1LB6"
SQ   SEQUENCE   522 AA;  59573 MW;  5AB9C255CCFEE749 CRC64;
     MSLLNCENSC GSSQSESDCC VAMASSCSAV TKDDSVGGTA STGNLSSSFM EEIQGYDVEF
     DPPLESKYEC PICLMALREA VQTPCGHRFC KACIIKSIRD AGHKCPVDNE ILLENQLFPD
     NFAKREILSL MVKCPNEGCL HKMELRHLED HQAHCEFALM DCPQCQRPFQ KFHINIHILK
     DCPRRQVSCD NCAASMAFED KEIHDQNCPL ANVICEYCNT ILIREQMPNH YDLDCPTAPI
     PCTFSTFGCH EKMQRNHLAR HLQENTQSHM RMLAQAVHSL SVIPDSGYIS EVRNFQETIH
     QLEGRLVRQD HQIRELTAKM ETQSMYVSEL KRTIRTLEDK VAEIEAQQCN GIYIWKIGNF
     GMHLKCQEEE KPVVIHSPGF YTGKPGYKLC MRLHLQLPTA QRCANYISLF VHTMQGEYDS
     HLPWPFQGTI RLTILDQSEA PVRQNHEEIM DAKPELLAFQ RPTIPRNPKG FGYVTFMHLE
     ALRQRTFIKD DTLLVRCEVS TRFDMGSLRR EGFQPRSTDA GV
//
